Comparative impact of low body mass index on patients undergoing transcatheter or surgical aortic valve replacement by Tang, Diane Choun Houy
Boston University
OpenBU http://open.bu.edu
Theses & Dissertations Boston University Theses & Dissertations
2017
Comparative impact of low body
mass index on patients undergoing
transcatheter or surgical aortic
valve replacement
https://hdl.handle.net/2144/24028
Boston University
   
 
BOSTON UNIVERSITY 
 
SCHOOL OF MEDICINE 
 
 
 
 
 
Thesis 
 
 
 
 
 
COMPARATIVE IMPACT OF LOW BODY MASS INDEX ON PATIENTS  
 
UNDERGOING TRANSCATHETER OR SURGICAL AORTIC VALVE  
 
REPLACEMENT 
 
 
by 
 
 
 
 
DIANE CHOUN HOUY TANG 
 
B.A., Boston University, 2015 
 
 
 
 
 
 
 
 
Submitted in partial fulfillment of the 
 
requirements for the degree of 
 
Master of Science 
 
2017  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2017 by 
 DIANE CHOUN HOUY TANG 
 All rights reserved  
   
 
Approved by 
 
 
 
 
First Reader   
 Louis J. Toth, Ph.D.
 Assistant Professor, Department of Anatomy and Neurobiology 
 
 
Second Reader   
 Isaac George, M.D.  
 Assistant Professor of Surgery 
 Columbia University, College of Physicians and Surgeons 
 
 
Third Reader   
 Catherine Wang, M.D., M.B.A.  
 Director of Research and Development, CTS Research Lab 
 Columbia University, College of Physicians and Surgeons 
 
 
 iv 
 
ACKNOWLEDGMENTS 
 
I would like to thank Professor Louis J. Toth, Liqiong Fan, Joo-Eun Park and everyone in 
the Cardiothoracic Surgery Research Laboratory at Columbia University Medical Center 
for their unwavering support and aid. I especially want to express my gratitude towards 
Dr. Isaac George for guiding me through this whole process and Dr. Catherine Wang for 
being such an incredible mentor and advocate this past year. Last but not least, thank you 
to my family and my boyfriend for always being there. Thank you all for your time and 
instruction and for allowing me to be part of this incredible opportunity.  
 v 
 
COMPARATIVE IMPACT OF LOW BODY MASS INDEX ON PATIENTS 
UNDERGOING TRANSCATHETER OR SURGICAL AORTIC VALVE 
REPLACEMENT 
DIANE CHOUN HOUY TANG 
ABSTRACT 
Objective: This study aims to corroborate recent research demonstrating that patients 
with low body mass indexes tend to have worse postoperative survival outcomes 
compared to normal BMI patients. It also intends to compare survival outcomes and 
postoperative complications in transcatheter and surgical aortic valve replacement 
patients to determine which procedure, TAVR or SAVR respectively, is better for this 
challenging low BMI patient population. 
Methods: This is a retrospective, single-center study comparing patient data collected 
from 2000-2013 at New York Presbyterian Hospital/Columbia University Medical 
Center. Patients were dividing into three groups on the basis of BMI and aortic valve 
procedure: low BMI SAVR (BMI < 22 kg/m2; n = 148; 20.36%), normal BMI SAVR 
(22-25 kg/m2; n = 458; 63.00%), and low BMI TAVR (< 22 kg/m2; n = 121; 16.64%). 
There is a total of 606 SAVR patients and 121 TAVR patients. To corroborate recent 
research that low BMI patients tend to fare worse than normal BMI patients, an 
unadjusted comparison were used to compare baseline demographics and postoperative 
outcomes of 148 low BMI patients who underwent SAVR with 458 normal BMI patients 
who underwent isolated SAVR. These cohorts were then compared via a Kaplan-Meier 
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survival analysis and the log-rank test for 30 days, 6 months, 1 year and 3 years survival 
outcomes. 
The 148 low BMI SAVR patients were then compared to 121 low BMI patients 
who underwent TAVR on baseline demographics and preoperative risk factors. The two 
cohorts were compared using the Kaplan-Meier analysis and postoperative complications 
were compared utilizing a multivariable logistic regression after adjustment for age, 
gender, BMI and STS Scores. 
Results: The unadjusted analysis of the low BMI and normal BMI SAVR cohorts 
displayed similar patient demographics and preoperative risk factors. The normal BMI 
group demonstrated higher EF (55% vs. 51.5%; p = 0.002) and incidence of HLD 
(47.68% vs. 37.76%; p = 0.038). Conversely, the low BMI cohort had more females 
(61.49% vs.42.79%; p < 0.001) and individuals with a history of Afib (27.78% 
vs.16.96%; p = 0.004). As shown in the Kaplan Meier curve, the normal BMI SAVR 
patients exhibited superior 6 months, 1 year and 3 years survival rates and low BMI was 
shown to be a significant independent predictor of mortality (HR 2.56; 95% CI: 1.47 – 
4.47; p = 0.0009 at 1 year). The two groups had similar postoperative outcomes, 
however, the low BMI cohort had longer overall hospital stays (8 vs. 6.5 days; p = 
0.0003). 
The low BMI SAVR and TAVR patient cohorts varied significantly on most 
patient demographics and preoperative risk factors. The low BMI TAVR patients tend to 
be older (95.04% vs. 55.41% of patients > 75 years old) and had higher STS Scores 
(10.41 vs. 3.88; p < 0.0001). They also demonstrated significant increases in all the 
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preoperative risk factors excluding DM and prior CVA. The SAVR patients had 
significantly longer overall hospital stays (8 vs. 6 days; p < 0.0001), more re-exploration 
for bleeding (5.41% vs. 0.85%; p = 0.0411) and more patients discharged to home 
(68.24% vs. 50.85%; p = 0.0039) while the TAVR patients demonstrated higher rates of 
GI bleed (3.39% vs. 0.00%; p = 0.0240) and new PPM (10.17% vs. 0.68%; p = 0.0004). 
The low BMI SAVR cohort demonstrated better survival rates at 1 year and 3 years and 
low BMI TAVR was determined to be a significant independent predictor of mortality 
(HR 0.51; 95% CI: 0.30 – 0.88; p = 0.0146 at 1 year).  After controlling for specific 
covariates in the multivariate logistic regression analysis, the low BMI SAVR had 1.73 
times longer ICU stays, 1.90 times longer hospital stays and the odds of being discharged 
home was 17% less than the TAVR group (p = 0.0005, <0.0001, 0.5665).  
Conclusion: Although the rates of postoperative complications are fairly similar, patients 
with low BMIs demonstrated worse survival outcomes when compared to the normal 
BMI SAVR patients. With the current analysis, low BMI TAVR patients had a 
significantly worse preoperative profile compared to the corresponding SAVR cohort 
which explains the worse survival and postoperative outcomes. Despite this, the 
multivariable analysis showed that the low BMI SAVR patients had longer ICU and 
hospital stays as well as fewer discharges to home. As this is an ongoing study, steps 
should be made to balance the preoperative profile such that the low BMI SAVR and 
TAVR groups are comparable prior to survival and postoperative assessment. However, 
at the current status, TAVR has proven itself to be the preferred treatment for low BMI 
patients.  
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INTRODUCTION 
Overview of Aortic Stenosis 
One in every eight patients within the elderly population (> 75 years old)—an 
estimated prevalence of 12.4%—has aortic stenosis (AS) and the prevalence of AS is 
directly correlated with increasing age (Deutsch et al., 2013; Nkomo et al., 2006; 
Osnabrugge et al., 2013). As a matter a fact, the most common source of cardiovascular 
problems is aortic value abnormalities that result in AS (Faggiano et al., 2006; Iung & 
Vahanian, 2011). With our growing aging population, it becomes imperative to determine 
the optimal treatment for those suffering from prevalent maladies such as severe, 
symptomatic aortic stenosis.  
AS can encompass narrowing of any part of the aorta, for example stenosis of the 
ascending aortic root, but in this paper, AS is specifically used to refer to aortic valve 
stenosis. AS is a progressively degenerative aortic valve disease in which the aortic valve 
is narrowed due to valve calcification and thickening resulting in improper, obstructed 
blood flow to the body (Faggiano et al., 2006; Hu, 2012; Patel & Kirtane, 2016). 
Generally the aortic valve area is 3-4 cm2 but severe aortic valve stenosis is considered < 
1 cm2 (Bonow et al., 2006). In the majority of patients, AS is caused by gradual 
degeneration, valve thickening and/or calcification of the aortic valve that instigates 
restriction of its opening. When AS occurs, quality of life is significantly impaired with 
patients experiencing symptoms such as angina, chest tightness, dyspnea on exertion, 
shortness of breath, fatigue, heart palpitations and syncope (Baumgartner, 2005). 
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Because AS generally has an asymptomatic, latent period, many patients don’t seek 
treatment until they have progressed into severe AS and begin experiencing symptoms. 
At this point, their prognosis is grim. If their severe AS is left untreated, it can progress to 
left ventricular systolic dysfunction and with the increasing obstruction and subsequent 
myocardial overload, this would eventually lead to heart failure and death within two to 
three years after appearance of symptoms (Baumgartner, 2005). 
The only definitive therapeutic option for AS in adults is aortic valve replacement. 
However, early pharmacologic intervention, such as diuretics and angiotensin converting 
enzyme (ACE) inhibitors, can mitigate AS symptoms and prolong the need for surgery 
(Baumgartner, 2005; Reinöhl et al., 2015; Yurek et al., 2015). 
 
Aortic Valve Replacement (AVR) Techniques 
Surgical Aortic Valve Replacement (SAVR) 
Since the 1960s, the gold standard of care for severe aortic stenosis has been 
open-heart surgical aortic valve replacement (SAVR) (Baumgartner, 2005). SAVR has 
been shown over the years to have a significant improvement over optimal medical 
therapy with studies citing survival at 3 years being as high as 87% in SAVR patients 
compared to 21% in patients who received optimal medical therapy (as shown in Figure 
1), (Schwarz et al., 1982). SAVR’s vast superiority over optimal medical therapy for 
addressing severe AS has been widely accepted among clinicians (Hu, 2012).   
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Figure 1. Natural history of AS increases dramatically after onset of symptoms; 
without surgical intervention, mortality increases dramatically. Medical 
treatment for the cohort denied surgical aortic valve replacement (AVR or SAVR) 
included palliative care, medicine such as ACE inhibitors, and balloon aortic 
valvuloplasty to mitigate aortic stenosis symptoms (Cribier et al., 1986). As displayed 
in the graph, prognosis for severe aortic stenosis is poor with 21% survival at 3 years 
after onset of symptoms for medically treated individuals. On the contrary, survival 
for the surgical AVR group at 3 years was 87% (Schwarz et al., 1982). Image 
reproduced from “TAVR and SAVR: Current Treatment of Aortic Stenosis” (Hu, 
2012; Schwarz et al., 1982). 
 
Although SAVR is known to reduce AS symptoms and improve overall survival, in 
clinical practice, approximately 30-48% of patients present a prohibitive risk for surgical 
intervention. These patients could be deemed inoperable due to a number of factors 
including advanced age and/or certain comorbidities such as renal failure that greatly 
increase calculated risk for peri- and post-operative mortality (Deutsch et al., 2013; Hu, 
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2012). Patients are also contraindicated for SAVR if they cannot tolerate blood thinning 
medication or if they are currently being treated for bacterial infection. If patients did not 
qualify for SAVR, the mainstay treatment of severe, symptomatic AS, their only option is 
medical therapy that functioned as palliative care (C. Smith et al., 2011; Cribier et al., 
1986). 
 
Transcatheter Aortic Valve Replacement (TAVR) 
With the help of Dr. Anderson’s first transcatheter aortic valve implantation 
(TAVI, more commonly known as TAVR) in a pig in 1992 and later, Dr. Cribier’s first-
in-human implantation in 2002, a new movement commenced to address this unfulfilled 
clinical need and to tend to patients denied the option of SAVR. A minimally-invasive 
catheter-based approach, TAVR was a promising alternative for treating these patients 
(Hu, 2012).  
 Unlike SAVR which requires a sternotomy by cardiothoracic surgeons to access 
the aortic valve, TAVR involves the threading of a transfemoral (TF), transapical (TA), 
or transaortic (TAo) catheter to the damaged, stenotic valve. In addition, while SAVR 
involves the physical removal of the aortic valve, in TAVR, the native valve remains and 
instead is displaced by expansion of a new valve. Expansion of the new bioprosthetic 
pericardial valve exploits the calcification of the damaged valve to facilitate its adherence 
to the aortic annular area. Once the new steel mesh framed valve is embedded within the 
area of the previous valve, the new valve may begin to function (C. Smith et al., 2011). 
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This nonsurgical approach evades the need for an invasive sternotomy and a 
cardiopulmonary bypass machine while offering a critically needed alternative therapy 
for AS patients who have been deemed inoperable or high risk for surgical intervention 
(Deutsch et al., 2013; Hu, 2012). Since the first-in-human TAVR in 2002, this procedure 
has been performed over 200,000 times by the end of 2015 (Tang, Lansman, & Panza, 
2015). As shown in Figure 2, TAVR has become more pervasive in lower risk AS patient 
populations and TAVR programs have even begun opening in hospitals around the world 
due to its remarkable success. 
Figure 2. Basic schematic illustrating the expansion of TAVR into lower surgical 
risk patients through further studies in the PARTNER trials. The enlarged sections 
of the pie chart indicate the patient populations in which TAVR has become available as 
an alternative treatment option to SAVR. Low, intermediate, and high risk groups are 
determined based on the Society of Thoracic Surgeons (STS) risk model (low risk >4%, 
moderate risk 4-8% and high risk > 8%). The untreated group represents any patients 
who do not qualify for SAVR. Sample populations for each of the PARTNER (Placement 
of AoRTic TraNscathetER) trials are outlined briefly along with the specific 
bioprosthetic aortic valve studied in the trial. Note the timeline is not directly correlated 
to the time lengths of the individual PARTNER trials. 
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Contrasting TAVR vs. SAVR in the PARTNER Trial 
The PARTNER (Placement of AoRTic TraNscathetER) Trial has been pivotal in 
the recent widespread adoption of TAVR. It is the first multicenter randomized control 
trial to compare the postoperative outcomes and survival rates of patients undergoing 
TAVR, SAVR or standard medical therapy across the United States (Mack et al., 2015). 
 
Surgical Risk 
In the PARTNER trials, patients are stratified and assessed based on their surgical 
risk, which is the expected mortality and/or morbidity from a surgical procedure. A 
patient’s surgical risk is mainly determined by risk calculators which accounts for a large 
number of preoperative factors that may play a role in a patient’s outcome after his/her 
surgery. These factors include patient demographics, type of surgery and comorbidities 
(Hu, 2012; Osnabrugge et al., 2013). Although these risk algorithms account for a large 
amount of information, there are a number of factors they do not consider in their 
computation such as frailty, the presence of a porcelain aorta, liver cirrhosis, and hostile 
chest (Raheem & Popma, 2012). Therefore, clinical judgement also plays a major role in 
determining surgical risk (Hu, 2012; Osnabrugge et al., 2013). 
 
Society of Thoracic Surgeons (STS) Risk Score 
In the PARTNER trial, the risk calculator utilized was the Society of Thoracic 
Surgeons (STS) Risk Score. In the late 1980s, the Society of Thoracic Surgeons began to 
collect data to generate an adult cardiac surgical database. With this data, the STS 
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developed risk models that enable surgeons to obtain a single, concise composite score 
that detailed the surgical risk of their patients. This composite score was known as the 
STS Score. The STS Score has evolved to become the most common measure used to 
evaluate cardiac surgery quality and to generate risk-adjusted mortality rates. It accounts 
for patient demographics, preoperative risk factors, associated comorbidities, and the type 
of surgery. Armed with this information, the STS risk model computes the probability of 
mortality and of certain post-operative outcomes such as risk for permanent stroke, renal 
failure and reoperation.  
The initial goal of STS scores was to generate a method to risk-adjust cardiac 
surgery outcomes such that the severity of patients’ illnesses prior to surgery were taken 
into consideration when evaluating a hospital’s and/or a cardiac surgeon’s annual 
mortality count. Before the advent of STS Scores, the quality of cardiac surgery was 
determined solely by the frequency of patient death. An erroneous approach, it failed to 
account for hospitals that received patients already at greater risk of mortality. Excellent 
surgeons or hospitals would appear to have worse quality of care due to high rates of 
mortality when this was in fact due to caring for sicker patients. The algorithm for STS 
Scores considers these underlying conditions and summarizes overall risk of mortality 
with a single number (“History of the STS National Database,” 2017). 
Although STS Scores were initially use to level the playing field for evaluating 
quality of care, it has established itself as the metric for determining a patient’s course of 
treatment. Surgeons can use a patient’s STS Score, along with their own judgement, to 
risk stratify their patients and to advise for or against SAVR in patients with severe, 
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symptomatic AS (Hu, 2012). In the PARTNER trials, STS Scores were a major 
determinant in the stratification of patients into low risk (< 4%), intermediate/moderate 
risk (between 4-8%), and high risk (> 8%) cohorts. The inoperable cohort was 
determined based on STS Score and unaccounted for risk factors that preclude surgical 
intervention (Leon et al., 2016).  
 
Overview of PARTNER Trials (2007 – 2016) 
As of now, there have been three main subdivisions of the PARTNER trial 
comparing TAVR and SAVR in a number of different aortic valve models (SAPIEN, 
SAPIEN XT and SAPIEN 3), (Tang et al., 2015). The PARTNER I trial was the first 
randomized control trial that evaluated TAVR outcomes in the United States. It was 
subdivided into two studies: PARTNER A and PARTNER B (refer to Figure 3). In 
PARTNER A, TAVR was prospectively compared to SAVR within a high surgical risk 
(STS Score > 8%) patient population. PARTNER B compared TAVR with standard 
therapy (medication or balloon aortic valvuloplasty) in patients who were ineligible for 
SAVR. The TAVR cohorts were found to have either a significantly increased 
(PARTNER B) or, at the least, similar survival rates (PARTNER A) at the primary 
endpoint—all-cause mortality or disabling stroke according to Kaplan Meier analyses (C. 
Smith et al., 2011). 
In PARTNER B, the advantage of TAVR over optimal medical therapy persisted 
at 5-year follow-up and all heart failure symptoms were shown to be less severe in the 
patients randomized to TAVR. Furthermore there was no evidence of bioprosthetic 
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degeneration or restenosis at 2 years (Mack et al., 2015). While there are many positive 
outcomes from the patients who underwent TAVR, there were also some unexpected, 
observed complications. For instance, SAVR patients exhibited low incidences of post-
procedural stroke even in high surgical risk groups; however, in the TAVR populations, 
the incidence of stroke was substantially increased. Other adverse events observed in the 
TAVR cohort include conduction disturbances which required the need for a permanent 
pacemaker (PPM), paravalvular leak (PVL), possibly due to improper fit of bioprosthetic 
valve, major vascular complications, and major bleeding. The incidence of these 
complications may be attributed to the novelty of the TAVR technique and valves. With 
time, these outcomes have been improving. This may be related to the learning curve 
necessary to understand new procedures. For instance, cardiac teams must learn how to 
properly interact during TAVR, surgeons must enhance their fluidity with TAVR-
associated technical skills, and developers must develop further innovations in 
bioprosthetic aortic valve technology (Hu, 2012; Tang et al., 2015). 
The PARTNER A trial exhibited similar survival rates to the SAVR group from 
30 day to 3-year follow-up (Mack et al., 2015). In contrast to PARTNER B, the 
PARTNER A TF TAVR cohort demonstrated similar incidences of stroke while the 
TA/TAo TAVR cohort displayed a higher incidence of stroke than the SAVR cohort. The 
TA/TAo TAVR group were excluded from TF TAVR because they had severe peripheral 
disease that prevented TF access and increasing their initial risk of stroke (Hu, 2012; C. 
Smith et al., 2011). The TAVR cohorts overall exhibited reduced acute kidney injury and 
severe bleeding. Similar to the PARTNER B arm, the TAVR cohort also demonstrated 
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greater incidences of major vascular complications, major bleeding and new-onset atrial 
fibrillation (Mack et al., 2015).  
In both subsets of the PARTNER trial, TAVR patients recuperated quicker due to 
the less-invasive approach which permitted them to leave the hospital earlier than 
expected compared to SAVR and they demonstrated an overall improvement in quality of 
life (QOL) with their new aortic valves. With these PARTNER trials, TAVR proved 
itself a viable alternative therapy to SAVR (C. Smith et al., 2011; Tang et al., 2015). 
After the publication of the PARTNER B trials, in 2011, Food and Drug Administration 
(FDA) approval was obtained for the Edwards Lifescience SAPIEN value in inoperable 
patients. Shortly after in 2012, the results of PARTNER A were revealed and FDA 
approval was obtained for the SAPIEN valve in high risk patients (Hu, 2012). 
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Figure 3. Study design schematic of analyzed cohorts in PARTNER I, PARTNER II 
and PARTNER II S3. PARTNER I (2007 - 2011) is shown at the top (C. Smith et al., 
2011; Svensson et al., 2013), PARTNER II (sometimes referred to as PARTNER II XT; 
2011 - 2014), in the middle (Leon et al., 2016), and PARTNER II S3 (2013 - 2014) at the 
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bottom (Herrmann et al., 2016). The PARTNER III trial, not shown in Figure 3, was 
initiated in 2016 and aims to evaluate TAVR in the low surgical risk patients (“The 
PARTNER 3 - Trial - The Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart 
Valve in Low Risk Patients With Aortic Stenosis,” 2017). 
 
With the astonishing success of the PARTNER I trial, the PARTNER II trial 
(including PARTNER IIA, IIB, S3i and S3HR) sought to investigate the benefits of 
TAVR in the intermediate/moderate surgical risk population (STS Score between 4-8%) 
using the second-generation of the SAPIEN value, the SAPIEN XT valve, which was 
created to correct for some of the first model’s glitches including better fit to decrease the 
incidence of PVL and need for new PPM (Tang et al., 2015; Webb et al., 2015). 
PARTNER II S3i and PARTNER II S3HR were similar to the PARTNER IIA 
and IIB trials but evaluated the newest iteration of the SAPIEN valve, SAPIEN 3, in 
inoperable and intermediate-risk patient cohorts respectively. The PARTNER II S3 trial 
was unique from its predecessors in that instead of utilizing a randomized control trial, it 
contrasted the results from the SAPIEN 3 TAVR cohort with the surgical arm of the 
PARTNER IIA trial (Rao, Maniar, & Zajarias, 2015). Herrmann et al. (2016) used a 
multivariable analysis to compare the groups in the inoperable cohort, PARTNER II 
S3HR and Thourani et al. (2016) used a propensity score matching analysis for the 
comparison of the intermediate risk patients to the PARTNER IIA SAVR patients. 
 
Propensity Score Matching Analysis 
A propensity score matching (PSM) analysis is a type of regression model that 
attempts to equate patients based on observed covariates such that their outcomes can be 
compared. In an ideal study comparing the effectiveness of a novel treatment over the 
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standard, a researcher would want to have the same patient undergo both procedures and 
compare the postoperative outcomes. Since this is not possible, the closest method to 
statistically equate two treatment groups is to utilize regression models. In PSM, patients 
are paired or matched together based on a number of preoperative parameters in order to 
simulate having the same patient undergo both procedures. By pairing individuals such 
that they have similar baseline starting points, this reduces bias or confounding variables 
and mimics a randomized control trial (Curtis, Hammill, Eisenstein, Kramer, & Anstrom, 
2007). 
Since TAVR is a relatively new procedure, in clinical practice, patients are 
suggested to undergo TAVR only if they are predicted to have poor prognosis with 
SAVR (Hu, 2012; van der Boon et al., 2013). Thus, many studies contrasting TAVR and 
SAVR are retrospective, observational studies which require the use of regression models 
such as PSM or an inverse probability weighting model to account for possible 
imbalances between the two cohorts. Despite the fact that the TAVR cohort may have 
patients with higher surgical risk, regression models counteract this by using weighing 
and/or matching in order to generate groups with similar preoperative covariates for 
postoperative comparison (Curtis et al., 2007).  
 
Further Detail on PARTNER II S3 
The PARTNER II S3 trial received criticism because it did not adhere to the 
statistical rigor of the previous trials which used the golden standard of a randomized 
control trial.  Nevertheless, utilizing a PSM model is the considered the next best way to 
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simulate the ideal study since it accounts for many baseline covariates. With the PSM 
model, SAPIEN 3 demonstrated significantly improved outcomes on almost every 
parameter when compared with the participants in the SAVR PARTNER IIA cohort. 
In the previous PARTNER trials, at two year outcomes, TAVR demonstrated at 
the least, parity with the SAVR arm but with PARTNER II S3, the results were 
sufficiently robust to exult TAVR as not merely an alternative to surgery, but as the 
preferred therapeutic option. At 1 year, SAPIEN 3 TAVR participants exhibited 
significantly lower rates of mortality, stroke, and paravalvular leak. Similar to the 
previous trials, moderate to severe PVL and new PPM implantation were still more 
common in the TAVR cohort (Rao et al., 2015). Nonetheless, the SAPIEN 3 TAVR 
cohort still proved superior to its previous iterations in these respects and in 2014 and 
2015, the FDA approved the SAPIEN XT valve and the SAPIEN 3 valve, respectively, 
for intermediate risk patients (Health, 2016; Kheradvar et al., 2015).  
 
Future of TAVR 
The PARTNER trials have been significant in the acceptance of TAVR because 
they proved the non-inferiority of TAVR to SAVR. Because of the success of the 
PARTNER trial along with other similar trials around the world, there is currently a 
worldwide trend to extend TAVR to lower risk patients (as mentioned in Figure 2), 
(Herrmann et al., 2016). TAVR has been approved for commercial use in high and 
intermediate risk populations and in the near future, PARTNER III will be investigating 
the outcomes of TAVR in the low surgical risk population (STS Score <4%). 
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Factors that may limit TAVR’s expansion into younger, low risk patients include 
the cost-effectiveness of TAVR compared to SAVR, the unknown long-term durability of 
TAVR bioprosthetic valves, and the concerns about what appears to be TAVR-specific 
post-procedural issues (such as higher incidences of PVL). Other potential complications 
include conduction defects (like new on-set atrial fibrillation), device embolization and 
coronary obstruction. 
The issues of cost-effectiveness continue to be addressed with advancements in 
valve technology. The TAVR-specific post-procedural complications may have appeared 
due to the learning curve required to learn novel techniques (Falk, 2014). The lower 
incidences in these complications may be attributed to the development of TAVR-
associated technical skills and improvement in overall TAVR procedure (Tang et al., 
2015). As for the durability of TAVR valves, there are ongoing studies evaluating its 
degeneration and incidence of restenosis (Harbaoui et al., 2016). With TAVR’s 
progression into low risk surgical groups, long-term durability of TAVR valves can be 
assessed. In hospitals, interdisciplinary heart teams consisting of cardiac surgeons, 
cardiologists and other specialists have assembled to collaborate on risk assessment of 
patients to evaluate these factors and determine which procedure is more suitability based 
on individual risk profiles (Al-Lamee, Godino, & Colombo, 2011). 
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Low Body Mass Index (BMI) 
Obesity Paradox 
Since the first PARTNER trial, TAVR has become established in specific patient 
subsets because of its non-inferiority to SAVR and its role is continuing to evolve in 
others. As TAVR progresses into lower risk patient populations, its success has 
stimulated investigations into whether TAVR can be used in specific patient populations 
that pose a challenge when surgical intervention is necessary (Herrmann et al., 2016). 
One of these patient populations is patients with low body mass indexes (BMIs). 
Although BMI’s predictive role in surgical risk has yet to be fully elucidated, 
studies have cited an inverse relationship between BMI and poor prognosis referred to as 
the obesity paradox. This phenomenon explains the observed, paradoxical relationship 
wherein lower BMIs tend to serve as a preventative health measure against 
cardiovascular disease; however, should the need for surgery arise, higher BMIs are 
associated with increased survival (R. Smith et al., 2012).  
One theory used to explain the obesity paradox is that improved outcomes in 
these higher BMI patients undergoing surgery may be due to increased physiological 
energy reserves necessary for recovery. Other theories include the neutralization of 
lipopolysaccharides with lipoproteins which limit the release of inflammatory cytokines. 
Frailty is often cited as the rationale used to explain the obesity paradox in regards 
to low BMI outcomes. Frailty can be conceptualized as increased susceptibility or 
impaired resistance to stressors which carries a high risk for adverse outcomes after 
cardiac surgery (Yamamoto et al., 2015). It is measured by unintentional weight loss (5 
 17 
kg/year), low BMI (<20 kg/m2), weakness in grip strength, serum albumin concentrations 
of < 3.5 g/dL, and low activity evaluated by slowness in gait speed (Fried et al., 2001; 
Yamamoto et al., 2015). Because low BMI can be associated to frailty, one theory is that 
these patients simply cannot bear the burden of recovery post-surgical intervention 
(Yamamoto et al., 2015).  
 
Current Research into the Obesity Paradox 
A national healthcare concern, obesity has been implicated as a risk factor for 
many predisposing conditions for cardiovascular disease such as hypertension (HTN), 
heart failure, diabetes mellitus (DM), atherosclerotic disease and coronary artery disease 
(Stamou et al., 2011). Once individuals have developed a number of chronic diseases, 
studies, such as that by Stamou et al. (2011), have indicated that higher BMIs tended to 
correlate with increased long-term survival and better procedural outcomes. Other 
studies, like that of Johnson et al. (2015), confirms this in patients undergoing coronary 
artery bypass graft (CABG) and showed that underweight patients had higher rates of 
mortality and increased adverse postoperative outcomes.  
There is a plethora of data corroborating the obesity paradox in various cardiac 
procedures such as CABGs but limited studies on the effect of BMI after SAVR. The 
studies that do address BMI after SAVR tend to endorse the obesity paradox, particularly 
in regards to higher risk for low BMI patients. Vaduganathan et al. (2012) suggests that 
underweight patients (<18.5 kg/m2) have significantly worse short and longer-term 
outcomes compared to other BMI strata and suggests more investigation into this cohort. 
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R. Smith et al. (2012), on the other hand, had evidence supporting the obesity paradox, 
however, it did not reach statistical significance.  
In general, studies support the existence of the obesity paradox in TAVR 
populations. The most recent study evaluating the effect of BMI and the obesity paradox 
in TAVR was a meta-analysis of 11 studies by Takagi, Umemoto, & ALICE (2016). This 
study concluded that higher BMI, reported in terms of continuous or categorical data, was 
associated with significantly less mortality. When BMI was reported in terms of 
continuous data, higher BMIs were associated with better early and mid-term survival 
after TAVR and when BMI was stratified as a categorical variable, the overweight or 
obesity category was associated with better early 30 day mortality. Konigstein et al. 
(2015) and van der Boon et al. (2013) also supported this conclusion demonstrating that 
individuals with BMIs in the obese and overweight categories were independently 
associated with better outcomes, such as lower risk of 30 day and 1 year mortality, after 
TAVR.  
Unlike the previously described research, Abramowitz et al. (2016) found no 
evidence for obesity paradox following TAVR but theorizes that this may be due to 
confounders such as not accounting for frailty. Although Abramowitz et al. (2016) was 
not able to investigate the low BMI population due to small sample size, Koifman et al. 
(2016) also credited the lack of consideration for frailty after concluding that low BMI (< 
20 kg/m2) was not associated with increased early or midterm mortality in TAVR 
patients.  
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Goal 
Although there are studies investigating the effect of BMI in SAVR and TAVR 
individually, there are no studies that directly compare outcomes for these two 
procedures. This study aims to first, compare low BMI and normal BMI patients who 
underwent SAVR to demonstrate that low BMI patients fare worse than normal BMI 
patients. Second, this study aims to compare TAVR and SAVR in a low BMI patient 
population to suggest that TAVR may be a better alternative to SAVR for treating severe 
aortic stenosis in this challenging patient population. 
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SPECIFIC AIMS 
In a growing aging population, the prevalence of severe, symptomatic AS patients 
is steadily increasing and replacement of the aortic valve is the only effective method to 
treat AS (Baumgartner, 2005; Reinöhl et al., 2015; Yurek et al., 2015). Although SAVR 
is the conventional method to replace the damaged valve, the movement towards 
minimally invasive procedures has fueled the advent of TAVR. Success in the 
PARTNER trials has stimulate researchers to investigate whether TAVR can be used in 
other challenging patient populations such as in low BMI patients.  
This study aims to address the paucity of data investigating TAVR and SAVR in 
low BMI populations and determine whether patients with low BMIs should undergo 
either TAVR or SAVR. To achieve this goal, this study consists of two major parts. The 
first part investigates low and normal BMI patients who underwent isolated SAVR to 
further explore the obesity paradox in regards to the low BMI population and substantiate 
the claim that low BMI patients fare worse after surgery compared to their normal BMI 
counterpart. The second part of the study aims to compares survival data and 
postoperative outcomes of the two alternative therapies for severe, symptomatic aortic 
stenosis, SAVR and TAVR, within a low BMI population.  
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METHODS 
Patients 
Individual patient data was obtained from 727 aortic valve replacements for 
severe aortic stenosis from 2000 to 2013 at New York Presbyterian Hospital/Columbia 
University Medical Center. Baseline demographics, preoperative risk factors and 
postoperative outcomes were collected based on retrospective chart review. From 2000 to 
2013, 148 patients underwent SAVR and had BMIs < 22 kg/m2 and 121 patients had 
BMIs < 22 kg/m2 and underwent TAVR. There were 458 patients that underwent SAVR 
and had BMIs between 22 kg/m2 and 25 kg/m2. This study met all guidelines of the 
Institutional Review Board of Columbia University and informed consent was waived. 
 
Definitions 
Individuals were categorized by type of AVR procedure and stratified into two 
different BMI groups. The low BMI group was defined as < 22 kg/m2 (n = 269; 37.00%) 
and normal BMI was defined as 22 kg/m2 to 24.99 kg/m2 (n = 458; 63.00%). The Society 
of Thoracic Surgeons’ national cardiac surgery database definitions were used for all 
preoperative and postoperative parameters.  
 
Data Analysis 
Univariate Analysis 
Descriptive statistics were utilized to summarize baseline patient characteristics, 
preoperative risk factors, and postoperative complications where postoperative 
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complications were described for the in-hospital postoperative period. Categorical 
variables were reported as frequencies and percentages and compared using the Pearson’s 
χ2 test or Fisher’s exact test, depending on the distribution of the data. Continuous 
variables were summarized using medians and interquartile ranges and they were 
compared via the two-sample independent t test or Wilcoxon Rank-Sum test for non-
normally distributed data where a probability value of less than 0.05 (p < 0.05) was 
deemed statistically significant.  
 
Univariate comparisons were performed on preoperative and postoperative 
variables between normal BMI and low BMI SAVR patients to exhibit an unadjusted 
comparison of the two groups. Univariate comparisons were also performed on 
preoperative and postoperative variables of the unadjusted and adjusted low BMI SAVR 
and low BMI TAVR cohorts. 
 
Postoperative Outcomes 
The primary outcome was death from any cause. Secondary outcomes included 
length of ICU stay, length of hospital stay, MI, stroke, new-onset hemodialysis, GI bleed, 
re-exploration for bleeding, left ventricular ejection fraction (EF), new PPM, and 
discharge to any location other than home. 
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Kaplan Meier Survival Analysis 
With a 100% follow-up rate, overall survival time was defined as time since 
surgery which was pinpointed as the last known patient follow-up date or death date, 
whichever came later. Survival curves were constructed using the Kaplan-Meier survival 
analysis and compared with the log-rank test. All analyses were conducted using SPSS 
with significance being defined as a two-sided p-value of 0.05.  
 
Multivariable Logistic Regression 
Multivariable logistic regression was used to identify independent predictors of 
mortality with results reported as hazard ratios or estimated outcome difference/odd ratio 
(OR) with a 95% confidence interval. 
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RESULTS 
Normal BMI SAVR vs. Low BMI SAVR 
 The baseline demographics of the patients undergoing SAVR are summarized in 
Table 1. The median BMI for the low BMI SAVR group was 20.6 kg/m2 (19.25 kg/m2 - 
21.38 kg/m2) and the median for the normal BMI SAVR group was 23.7 kg/m2 (22.96 
kg/m2 - 24.38 kg/m2). 
Compared to the normal BMI SAVR cohort, the low BMI cohort had significantly 
more females (61.49% of low BMI SAVR vs.42.79% of normal BMI SAVR, p < 0.001) 
and higher incidences of atrial fibrillation (Afib) (27.78% vs.16.96%, p = 0.004). The 
normal BMI SAVR, on the other hand, exhibited significantly higher EF (55% for the 
normal BMI SAVR vs. 51.5% for the low BMI, p = 0.002) and higher incidences of 
hyperlipidemia (HLD), (47.68% vs. 37.76%, p = 0.038). 
Although not statistically significant, the low BMI SAVR group appeared to have 
more individuals in the older age ranges of between 50 years old to 75 years old and 
greater than 75 years old (36.49% vs. 33.41% in >50 - ≤ 75 years old  and 55.41% vs. 
53.93% in >75 years old). The median STS Score for the low BMI SAVR patients at 3.89 
(1.84-6.40) was slightly lower than the normal BMI group at 4.75 (3.01-6.00; p = 0.475). 
The low BMI SAVR had higher incidences of HTN (67.36% vs. 65.64%; p = 0.704), 
cardiogenic shock (0.68% vs. 0.44%; p = 0.573), prior cerebrovascular accident (CVA) 
(9.46% vs. 8.15%; p = 0.619), prior myocardial infarction (MI) (13.51% vs. 13.32%; p = 
0.952) and history of percutaneous coronary intervention (PCI) (14.69% vs. 13.66%; p = 
0.756). On the contrary, the normal BMI SAVR had marginally higher incidences of DM 
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(14.07% vs. 11.49%; p = 0.424), history of peripheral vascular disease (PVD) (6.86% vs. 
6.76%; p = 0.966), history of endocarditis (6.59% vs. 4.90%; p = 0.462), history of 
cardiac surgery (21.76% vs. 17.57%; p = 0.275), and congestive heart failure (26.64% vs. 
26.35%; p = 0.945). 
Table 1. Unadjusted Comparison of Demographic and Preoperative Risk Factors in 
the Low BMI SAVR Cohort and the Normal BMI SAVR Cohort. Note that the 
normal range for ejection fraction is 55-70%. Ejection fraction measures the percent of 
blood leaving the heart each time it contracts so higher ejection fractions are generally 
indicative of a healthy heart. 
  Low BMI SAVR Normal BMI SAVR  
  (n = 148) (n = 458) p-value 
Demographics    
Age    
       ≤ 50 years 12 (8.11%) 58 (12.66%) 0.307 
       > 50 - ≤ 75 years 54 (36.49%) 153 (33.41%)  
       >75 years 82 (55.41%) 247 (53.93%)  
Sex (female) 91 (61.49%) 196 (42.79%) <0.001 
BMI (kg/m2) 20.6 (19.25-21.38) 23.7 (22.96-24.38) <0.0001 
Preoperative Risk Factors 
STS Score 3.89 (1.84-6.40) 4.75 (3.01-6.00) 0.475 
Ejection Fraction (%) 51.5 (36-55) 55 (45-60) 0.002 
Diabetes Mellitus 17 (11.49%) 64 (14.07%) 0.424 
Hypertension 97 (67.36%) 298 (65.64%) 0.704 
Hyperlipidemia 54 (37.76%) 216 (47.68%) 0.038 
Cardiogenic Shock 1 (0.68%) 2 (0.44%) 0.573 
Prior CVA 14 (9.46%) 37 (8.15%) 0.619 
Prior MI 20 (13.51%) 61 (13.32%) 0.952 
History of PVD 10 (6.76%) 31 (6.86%) 0.966 
History of PCI 21 (14.69%) 62 (13.66%) 0.756 
History of Endocarditis 7 (4.90%) 30 (6.59%) 0.462 
History of Cardiac Surgery 26 (17.57%) 99 (21.76%) 0.275 
Atrial fibrillation 40 (27.78%) 77 (16.96%) 0.004 
Congestive Heart Failure 39 (26.35%) 122 (26.64%) 0.945 
 
Shown in Figure 4 are the Kaplan Meier curves comparing survival estimates in 
the low BMI SAVR and the normal BMI SAVR cohorts. The unadjusted survival 
estimates demonstrated increased mortality at 6 months, 1 year, and 3 years in the low 
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BMI group (13.5%, 16.22%, 25.00%) compared to the normal BMI group (2.84%, 
5.02%, 5.68%, 10.48%), (p = 0.0051, 0.0009, <0.0001). Having low BMI was a 
statistically significant independent predictor of mortality (HR 2.56; 95% CI: 1.47 – 4.47; 
p = 0.0009 at 1 year) on multivariable regression analysis (refer to Table 2). 
 
Figure 4. Kaplan Meier Survival Curves for the Low and Normal BMI SAVR 
patient populations. Product-limit survival estimates were used to generate the Kaplan 
Meier curves. The top line in red represents the normal BMI SAVR cohort while the 
blue, bottom line represents the low BMI SAVR cohort. The shaded area represents the 
95% Hall-Wellner Bands confidence intervals of the survival curves.  
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Table 2. All-cause Mortality for Low BMI SAVR and Normal BMI SAVR. Mortality 
is shown here, however, to get percent survival, simply subtract the percent mortality by 
one hundred. The hazard ratios (HR) along with the p-values indicate that survival at 6 
months, 1 year and 3 years was significantly higher for the normal BMI SAVR cohort.  
 Survival Time Low BMI SAVR Normal BMI SAVR HR 95% CI p-value 
30 days 9 (6.08%) 13 (2.84%) 1.78 [0.76,4.17] 0.1847 
6 months  20 (13.5%) 23 (5.02%) 2.36 [1.30, 4.30] 0.0051 
1 year 24 (16.22%) 26 (5.68%) 2.56 [1.47,4.47] 0.0009 
3 years 37 (25.00%) 48 (10.48%) 2.49 [1.62, 3.83] <0.0001 
 
 Postoperative complications in the two groups were relatively similar with the 
only statistically significant outcome being the longer length of hospital stay (LOS 
Hospital) in the low BMI SAVR group (8 days vs. 6.5 days; p = 0.0003), (refer to Table 
3). 
As for the other parameters, the normal BMI SAVR group demonstrated a minor 
increase in rates of gastrointestinal (GI) bleed (0.87% vs. 0.00%; p = 0.5769), new PPM 
implantations (1.31% vs. 0.68%; p = 1.0000) and number of patients discharged to their 
home rather than another type of specialized care such as a skilled nursing facility 
(75.76% vs. 68.24%; p = 0.0700). 
Likewise, the low BMI SAVR group exhibited minor increases in MI (0.68% vs. 
0.00%; p = 0.2442), stroke (2.70% vs. 1.53%; p = 0.4764), new-onset hemodialysis 
(1.35% vs. 1.09%; p = 0.6808), and re-exploration for bleeding (5.41% vs. 3.93%; p = 
0.4413). Length of Intensive Care Unit (ICU) stay and the postoperative EF were the 
same in both groups (2 days; p = 0.0608), (55%; p = 0.1669).  
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Table 3. Postoperative Outcomes of Normal BMI SAVR and Low BMI SAVR. 
Length of hospital stay is determined as the time the individual remains in the hospital 
after their associated procedure (either SAVR or TAVR). 
  Low BMI SAVR Normal BMI SAVR   
  (n = 148) (n = 458) p-value 
LOS ICU (days) 2 (1-4) 2 (1-3) 0.0608 
LOS Hospital (days) 8 (5.5-11.0) 6.5 (5.0-9.0) 0.0003 
Myocardial Infarction 1 (0.676%) 0 (0.00%) 0.2442 
Stroke 4 (2.70%) 7 (1.53%) 0.4764 
New-onset hemodialysis 2 (1.35%) 5 (1.09%) 0.6808 
GI Bleed 0 (0.00%) 4 (0.87%) 0.5769 
Re-exploration for Bleeding 8 (5.41%) 18 (3.93%) 0.4413 
Ejection Fraction (%) 55 (44.5-60) 55 (50-60) 0.1669 
New Pacemaker 1 (0.68%) 6 (1.31%) 1.0000 
Discharged Home 101 (68.24%) 347 (75.76%) 0.0700 
 
Low BMI SAVR vs. Low BMI TAVR  
 There was a total of 269 low BMI patients, 148 (55.02%) of which underwent 
SAVR and 121 (44.98%) of which underwent TAVR. Baseline demographics and 
preoperative risk factors for the low BMI SAVR and low BMI TAVR patients are shown 
in Table 4. 
At baseline, female patients accounted for 61.16% of low BMI TAVR and 
61.49% of low BMI SAVR patients (p = 0.9560). The TAVR patients tended to be older 
with 95.04% of its participants being older than 75 yrs old, only 4.96% of patients being 
between 50 and 70 years old and zero patients being less than 50 years old. The low BMI 
SAVR only had 55.41% of its cohort older than 75 years old but the SAVR had more 
participants less than 50 years old (8.11%) and between the ages of 50 and 70 (36.49%) 
compared to the TAVR group. The BMI of both groups were similar with the median in 
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the low BMI SAVR group being 20.63 and the low BMI TAVR being 20.22 (p = 
0.3373). 
As expected, the low BMI TAVR group demonstrated significantly greater 
incidences of nearly all the preoperative risk factors evaluated. The low BMI TAVR 
group most notably had higher STS Scores at 10.41 (8.0-14.87) compared to the SAVR 
group’s 3.88 (1.84-6.40); p < 0.0001). There was also large increases in frequency of 
HLD (70.25% vs. 37.76%), history of PVD (30% vs. 6.76%), PCI (46.28% vs. 14.69%), 
and CHF (94.21% vs. 26.35%), (all of the above had a p-value < 0.0001). 
Also statistically significant, the TAVR cohort presented with higher incidences 
of HTN (85.95% vs. 67.36%; p = 0.0004), prior MI (30.58% vs. 13.51%; p = 0.0007), 
history of cardiac surgery (28.10% vs. 17.57%; p = 0.0390), and Afib (41.67% vs. 
27.78%; p = 0.0178).  
There were no other significant differences in baseline comorbidities. However, 
the TAVR cohort exhibited marginally higher frequencies of DM (20% vs. 11.49%; p = 
0.0542), cardiogenic shock (1.67% vs. 0.68%; 0.4432), and prior CVA (13.22% vs. 
9.46%; p = 0.3293). Likewise, the SAVR cohort had slightly greater incidences of 
patients with a history of endocarditis (4.90% vs. 1.67%; p = 0.1514) and lower 
preoperative EF (51.5% vs. 55%; p = 0.0493).  
 Of the low BMI TAVR procedures, there were 72 transfemoral (TF), 6 transaortic 
(TAo), and 43 transapical (TA) approaches (59.50%, 4.96%, and 35.54% respectively).  
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Table 4. Unadjusted Comparison of Patient Demographics and Preoperative Risk 
Factors for Low BMI Cohort.  
 Low BMI SAVR Low BMI TAVR p-value 
  (n = 148) (n = 121)   
Demographics       
Age    
       ≤ 50 yrs 12 (8.11%) 0 (0%) <0.0001 
       > 50 - ≤ 75 yrs 54 (36.49%) 6 (4.96%)  
       >75 yrs 82 (55.41%) 115 (95.04%)  
Sex (female) 91 (61.49%) 74 (61.16%) 0.9560 
BMI (kg/m2) 20.63 (19.25-21.38) 20.22 (18.65-21.22) 0.3373 
Preoperative Risk Factors  
STS Score 3.88 (1.84-6.40) 10.41 (8.0-14.87) <0.0001 
Ejection Fraction (%) 51.5 (36-55) 55 (35-62) 0.0493 
Diabetes Mellitus 17 (11.49%) 24 (20%) 0.0542 
Hypertension 97 (67.36%) 104 (85.95%) 0.0004 
Hyperlipidemia 54 (37.76%) 85 (70.25%) <0.0001 
Cardiogenic Shock 1 (0.68%) 2 (1.67%) 0.4432 
Prior CVA 14 (9.46%) 16 (13.22%) 0.3293 
Prior MI 20 (13.51%) 37 (30.58%) 0.0007 
History of PVD 10 (6.76%) 36 (30%) <0.0001 
History of PCI 21 (14.69%) 56 (46.28%) <0.0001 
History of Endocarditis 7 (4.90%) 2 (1.67%) 0.1514 
History of Cardiac Surgery 26 (17.57%) 34 (28.10%) 0.0390 
Atrial fibrillation 40 (27.78%) 50 (41.67%) 0.0178 
Congestive Heart Failure 39 (26.35%) 114 (94.21%) <0.0001 
 
As for postoperative outcomes (shown in Table 5), the low BMI SAVR patients 
had significantly longer lengths of overall hospital stay (8 days vs. 6 days; p < 0.0001), 
re-exploration for bleeding (5.41% vs. 0.85%; p = 0.0411) and more patients discharged 
to home (68.24% vs. 50.85%; p = 0.0039). In contrast, the low BMI TAVR patients 
demonstrated significantly higher rates of GI bleed (3.39% vs. 0.00%; p = 0.0240) and 
need for new PPM (10.17% vs. 0.68%; p = 0.0004). 
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Although not statistically significant, the low BMI TAVR exhibited greater 
frequencies in all of the other postoperative parameters: postoperative MI (2.54% vs. 
0.676%; p = 0.2139), postoperative stroke (5.08% vs. 2.70%; p = 0.3102), new-onset 
hemodialysis (1.69% vs. 1.35%; p = 0.8191), and higher EF (57% vs. 55%; p = 0.1023). 
The low BMI patients demonstrated similar lengths of ICU stay (2 days; p = 0.7343). 
 
Table 5. Unadjusted Comparison of Postoperative Outcomes of Low BMI SAVR 
and Low BMI TAVR. Since TAVR is a minimally invasive procedure, some of the 
postoperative parameters such as re-exploration for bleeding are unlikely to occur 
resulting in low event rates. 
  Low BMI SAVR Low BMI TAVR  
  (n = 148) (n = 121) p-value 
LOS ICU (days) 2 (1-4) 2 (1-3) 0.7343 
LOS Hospital (days) 8 (5.5-11.0) 6 (5-8) <0.0001 
Myocardial Infarction 1 (0.676%) 3 (2.54%) 0.2139 
Stroke 4 (2.70%) 6 (5.08%) 0.3102 
New-onset hemodialysis 2 (1.35%) 2 (1.69%) 0.8191 
GI Bleed 0 (0.00%) 4 (3.39%) 0.0240 
Re-exploration for Bleeding 8 (5.41%) 1 (0.85%) 0.0411 
Ejection Fraction (%) 55 (44.5-60) 57 (44-63) 0.1023 
New Pacemaker 1 (0.68%) 12 (10.17%) 0.0004 
Discharged Home 101 (68.24%) 60 (50.85%) 0.0039 
 
According to Figure 5 and Table 6, the 30 day mortality for the low BMI SAVR 
group was 6.08% compared to the low BMI TAVR group which was 8.26% (p = 0.4796). 
Mortality at 6 months was 13.51% and 19.01% (p = 0.0619) and mortality at 1 year was 
16.22% and 23.97% (p = 0.0146) respectively. At 3 years, mortality was 25.00% for the 
low BMI SAVR and 36.36% for the low BMI TAVR (p = 0.0005). Significant predictors 
of mortality on multivariate regression analysis included being in the low BMI TAVR 
group (HR 0.51; 95% CI: 0.30 – 0.88; p = 0.0146 at 1 year). 
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Figure 5. Kaplan Meier Survival Curves for the Low and Normal BMI SAVR 
patient populations. This Kaplan Meier Curve was formed using product-limit survival 
estimates with 95% Hall-Wellner Bands which are indicated as the shaded areas around 
the curve. The top line in blue represents the low BMI SAVR cohort while the bottom, 
red curve signifies the low BMI TAVR cohort. 
 
Table 6. All-cause Mortality for Low BMI SAVR and Low BMI TAVR.  
Survival Time Low BMI SAVR Low BMI TAVR HR 95% CI p-value 
30 days 9 (6.08%) 10 (8.26%) 0.72 [0.29, 1.78] 0.4796 
6 months 20 (13.51%) 23 (19.01%) 0.56 [0.31, 1.03] 0.0619 
1 year 24 (16.22%) 29 (23.97%) 0.51 [0.30,0.88] 0.0146 
3 years 37 (25.00%) 44 (36.36%) 0.46 [0.30, 0.71] 0.0005 
 
 For the multivariable regression, the postoperative outcomes of MI, Stroke, new 
on-set hemodialysis, GI bleed, re-exploration for bleeding, and new PPM were not 
analyzed due to the low incidence of occurrence which would lead to unreliable 
estimates. Table 7 displays the results of the multivariable regression after controlling for 
 33 
age, gender, BMI and STS Scores. As expected, the length of ICU stay among the low 
BMI SAVR group was 1.73 times longer than patients in the low BMI TAVR group 
(95% CI: 1.27, 2.35; p = 0.0005) and the LOS Hospital was 1.90 times longer than those 
in the TAVR group (95% CI: 1.56, 2.33; p < 0.0001). The odds of being discharged home 
was 17% less in the low BMI SAVR than the TAVR group (95% CI: 0.44, 1.56; p = 
0.5665).  
 
Table 7. Estimates Outcome Difference Between Low BMI SAVR and Low BMI 
TAVR Based on Multivariable Regression. This is the adjusted comparison of the low 
BMI groups which accounts for underlying differences in age, gender, BMI and STS 
scores. The other postoperative parameters, MI, Stroke, new on-set hemodialysis, GI 
bleed, re-exploration for bleeding, and new PPM, were not evaluated due to the low 
number of events for each parameter which may result in inaccurate, non-representative 
results. 
  Estimated outcome difference 95% CI p-value 
LOS ICU (days) 1.73 [1.27, 2.35] 0.0005 
LOS Hospital (days) 1.90 [1.56, 2.33] <0.0001 
Discharged Home 0.83 [0.44, 1.56] 0.5665 
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DISCUSSION 
 Although SAVR used to be the standard of care, with the advent of catheter-based 
technologies and the PARTNER trials, TAVR has expanded its role to become the 
approved therapeutic option in intermediate-risk patients and high-risk or otherwise 
inoperable patients with severe, symptomatic aortic stenosis. The purpose of this study 
was to prove that TAVR could also be the preferred treatment option over SAVR in low 
BMI patients, a very specific patient population. In interpreting the following results, it is 
essential to remember that this is an ongoing study and these are merely the preliminary 
results. Further data collection and data analysis are still in process.  
 
Obesity Paradox in Terms of Low BMI patients 
Before TAVR and SAVR can be compared in a low BMI population, this study 
first elucidates the need to study low BMI populations undergoing surgery. Isolated 
SAVR patients were divided into a low BMI (< 22 kg/m2; n = 148) and a normal BMI 
cohort (22-25 kg/m2; n = 458). They were then compared on all-cause mortality and 
preoperative and postoperative outcomes to substantiate previous claims that low BMI 
patients tend to fare worse than their normal BMI counterparts despite having a healthier 
preoperative profile. 
The sample size for the low BMI SAVR cohort will be increasing, as this is an 
ongoing project. Shown in Table 1 are the preliminary results of the unadjusted 
comparison of preoperative risk factors. These results corroborate the claim that low BMI 
patients have a healthier preoperative profile. This is directly indicated by the lower EF 
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(51.5% vs. 55%; p = 0.002) and lower STS Scores (3.89 vs 4.75; p = 0.475) which imply 
overall lower surgical risk. The normal BMI cohort was associated with higher rates of 
DM (14.07% vs. 11.49%; p = 0.424) and HLD (47.68% vs. 37.76%, p = 0.038) as 
predicted. The normal BMI group was also expected to more patients with HTN, 
however the increase in HTN in the low BMI SAVR group (67.36% vs. 65.64%; p = 
0.704) could be attributed to the small low BMI sample size. The small low BMI SAVR 
sample size could also explain the inability to reach statistical significance for the STS 
Score and the incidence of DM. 
The normal BMI cohort had younger individuals than the low BMI cohort. This 
may be because increasing BMI is directly correlated with the development of cardiac 
risk factors requiring surgery referral at a younger age in contrast to low BMI patients 
(Stamou et al., 2011). The other baseline characteristics did not reach statistical 
significance. Overall, Table 1 supports the theory that it is healthier to be in the low BMI 
category prior to requiring surgical intervention.  
Survival data supports the obesity paradox demonstrating an increase in mortality 
in low BMI patients at 6 months, 1 year and 3 years (13.5%, 16.22%, 25.00%) compared 
to the normal BMI group (2.84%, 5.02%, 5.68%, 10.48%), (p = 0.0051, 0.0009, <0.0001) 
despite possessing a better preoperative profile (shown in Figure 4 and Table 2). At 1 
year, having low BMI was a statistically significant independent predictor of mortality 
(HR 2.56; 95% CI: 1.47 – 4.47; p = 0.0009). As for postoperative outcomes shown in 
Table 3, the low BMI cohort required longer hospital stays after surgery. This fits with 
our conclusion that low BMI patients require more time to recover following an invasive 
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procedure such as SAVR. The other parameters did not reach statistical significance 
likely due to low event rate in the low BMI SAVR group. Again, this likely may be 
rectified with an increase in the low BMI sample size. 
 
Comparison of Low BMI TAVR vs. SAVR 
The unadjusted comparison of the low BMI SAVR and TAVR group in Table 4 
proved that the low BMI TAVR patients were at a gross disadvantage at baseline. The 
BMI range (20.63 kg/m2 vs. 20.22 kg/m2 respectively; p = 0.3373) and the proportion of 
female patients (61.49% vs. 61.6%; p = 0.9560) were equal in the SAVR and TAVR 
groups. Nevertheless, the TAVR patients were much older with 95.04% of its participants 
being older than 75 yrs old compared to the SAVR group’s 55.41%. There was no 
overlap in the STS Score interquartile ranges for the low BMI SAVR and TAVR groups 
(1.84 – 6.40 vs. 8.0 - 14.87; p <0.0001). The TAVR group contained mostly high surgical 
risk individuals (median 10.41) while the SAVR group contained mostly intermediate 
and low risk individuals (median 3.88; p < 0.0001). The TAVR group also demonstrated 
greater incidences of nearly all the preoperative risk factors with the exclusion of history 
of endocarditis (1.67% in low BMI TAVR vs. 4.90%; p = 0.1514)  and lower EF (55% in 
low BMI TAVR vs. 51.5%; p = 0.0493), (the TAVR cohort had a slightly improved 
ejection fraction compared to the SAVR cohort).  
The two cohorts are drastically different with the TAVR cohort having a 
significantly worse preoperative profile. Thus, the TAVR cohort was predicted to 
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perform worse in every parameter. Despite these expectations, the TAVR cohort had 
postoperative outcomes which were comparable to SAVR (Table 5).  
Further analysis of the postoperative complications in Table 5 show that the 
TAVR group exhibited greater rates of GI bleed (3.39% vs. 0.00%; p = 0.0240) and need 
for a PPM (10.17% vs. 0.68%; p = 0.0004) after the procedure. The TAVR cohort also 
presented with slightly greater, but not statistically significant, incidences of MI (2.54% 
vs. 0.676%; p = 0.2139), stroke (5.08% vs. 2.70%; p = 0.3102), and new-onset 
hemodialysis (1.69% vs. 1.35%; p = 0.8191). The low BMI TAVR cohort was expected 
to have increased need for new PPM and stroke post-TAVR due to previous trials 
comparing TAVR and SAVR (Hu, 2012). As for the four cases of GI bleed following 
TAVR, it is likely that the GI bleed was associated with an underlying condition. Stanger 
et al. (2016) linked patients with a previous history of gastroesophageal reflex disease 
(GERD) to a significant increase in GI Bleed post TAVR and three of the four patients 
demonstrated a history of GERD. The last patient had a history of gastroparesis. All four 
patients were in the older age category (84, 91, 92 and 93 years old). Overall, despite 
being at a higher surgical risk, the TAVR group had higher postoperative EF (57% vs. 
55%; p = 0.1023) and spent fewer days overall in the hospital (6 days vs. 8 days; p < 
0.0001).  
In the unadjusted postoperative outcomes comparison, the SAVR group had more 
patients discharged to home rather than a skilled nursing facility or a rehabilitation 
facility (68.24% vs. 50.85%; p = 0.0039). This is only because they had a significantly 
lower initial surgical risk profile.  
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In the multivariable logistic regression in Table 7, where age, gender, BMI and 
STS Scores were accounted for, TAVR established its superiority by permitting patients 
to recover quicker, as evidenced by the shorter ICU and hospital stays (low BMI SAVR 
patients had 1.73 times longer ICU stays and 1.90 longer hospital stays). Patients were 
then more likely to be discharged home rather than to a specialized care facility (0.83, 
95% CI: 0.44, 1.56; p = 0.5665). As a matter a fact, the odds of being discharged home 
were 17% less in the SAVR group. The SAVR cohort also had more frequent cases of re-
exploration for bleeding (5.41% vs. 0.85%; p = 0.0411) as expected since SAVR is 
inherently an invasive procedure.  
In the Kaplan Meier curve (Figure 5 and Table 6), the TAVR cohort demonstrated 
higher rates of mortality at 1 year (23.97% vs. 16.22%; p = 0.0146) and 3 years (36.36% 
vs. 25.00%; p = 0.0005) due to their high risk profile. Although this may appear to 
contradict the hypothesis that TAVR is better than SAVR in low BMI populations, it 
does not because the Kaplan Meier curve does not account for preoperative status. The 
TAVR cohort had significantly older patients who were already at high risk for mortality 
simply due to their advanced age. In addition, they had a high STS Score meaning that 
they had a large number of detrimental risk factors. In the present data, there is no 
evidence which credits the cause of their mortality. Because of this, the multivariable 
regression model is necessary to account for the preoperative imbalances present between 
the low BMI TAVR and SAVR cohorts. Since the final cause of their mortality is 
unknown (it could simply be due to advanced age and comorbidities instead of due to the 
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procedure or cardiovascular risk factors) length of hospital stay may be a better indicator 
of a patient’s status after the procedure. 
 
Study Limitations 
This study is limited by all limitations inherent to a single institution, 
retrospective analysis. Additionally, since this is not a randomized study, unmeasured 
confounding variables may also be implicit in the study. The low event rate of adverse 
outcomes lead to inconclusive statistical significance in the low BMI SAVR and normal 
BMI SAVR comparison. This could be resolved with an increase in the low BMI SAVR 
sample size.  
The study is also limited by the unadjusted comparisons between the treatment 
groups. To obtain the ideal research model as discussed in the introduction, the results 
would be more conclusive if preoperative factors could be balanced prior to comparison 
of postoperative complications via utilization of a propensity score matching model or an 
inverse probability weighting model. For example, in the comparison of low BMI and 
normal BMI SAVR, if the patients in the two groups could be matched based on age, 
gender and STS Scores such that their preoperative status are similar (that is, it is as if 
they are the same person but one person has low BMI and the other has a normal BMI), a 
causal relationship between BMI and postoperative complication rate and survival can be 
made. Likewise, the low BMI TAVR and SAVR patients could be matched based on age, 
gender, BMI and STS Score, to relay the benefit of a specific procedure, SAVR or 
TAVR, in the low BMI population. The STS Score would be an important parameter to 
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include as one of the matching variables because of its ability to assess patient 
demographics and preoperative risk factors and generate a single, composite risk score to 
predict postoperative survival. 
 
Future Studies 
Improvements to this study should include increasing the low BMI SAVR sample 
size and using a regression model that accounts for imbalances in preoperative covariates 
to compare treatment groups, such as propensity score matching model or an inverse 
probability weighting model.  
 
Why is BMI considered a valuable predictor of mortality? 
One theory is that BMI is important because it is theorized to be a good indicator 
of energy reserves that an individual needs when recovering. However, body surface area 
(BSA) has been determined to be a better indicator of metabolic mass (Fancher, Sacco, 
Gwin, Gormley, & Mitchell, 2015; Arsalan et al., 2016). There are different types of 
body mass and some types may be more useful to function as energy reserves after 
surgery. Because BMI cannot differentiate between fat, muscle or anything else that 
contributes to body mass, it may be unreliable and misleading. Interestingly, STS risk 
models utilize BSA instead of BMI in their computation of surgical risk (Shahian, 
Filardo, O’Brien, & Anderson, 2008). On the contrary, in a recent study, Arsalan et al. 
(2016) concludes that BMI may have more prognostic value compared to BSA after 
TAVR. In this case, there must be an alternative reason why BMI, which only accounts 
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for height and weight, has proven itself a valuable predictor of mortality. Some studies 
have linked improved outcomes in high BMI patients with lower systemic vascular 
resistance, plasma renin activity and circulating atrial natriuretic peptides (Mehra et al., 
2004; Stamou et al., 2011). A possible future study would be to identify biomarkers 
serum that explain the correlation between BMI and one’s survival after surgery.  
Another theory why BMI is important is that low BMI can be indicative of small 
anatomy and thus a small aortic annulus size. Patient populations with small aortic 
annulus size has been shown to have worse postoperative outcomes compared to normal 
aortic annulus size after SAVR because they require small prosthesis implantation. Small 
prosthesis implantation is often accompanied by reduced effective orifice areas and thus 
high transprosthetic gradients and recurrent AS which results in increased all-cause 
mortality (Pibarot & Dumesnil, 2006; Wang et al., 2013). TAVR has been suggested to 
be a better alternative therapy to SAVR in female patients due to their smaller aortic 
annulus (Rodés-Cabau et al., 2014). A prospective study may involve a trial evaluating 
survival after TAVR and SAVR with outcomes stratified by aortic annulus size, BMI and 
gender.  
Future studies can investigate why BMI has been shown to be a valuable predictor 
of mortality and what causes increasing BMI’s protective effect following TAVR or 
SAVR.  
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Relationship between Frailty and Low BMI 
Low BMI (< 20 kg/m2) is one of the frailty parameters. Afilalo et al. (2012) 
suggests that cardiac surgery risk models ought to assess frailty and disability status of 
patients in assessment of surgical risk, particularly in elderly patients who may require a 
more comprehensive model to evaluate their surgical risk. It would be interesting to 
evaluate which procedure, TAVR or SAVR, results in better postoperative outcomes 
based on level of frailty or level of disability. Many studies have shown the predictive 
value of frailty in appraising surgical risk and incidence of postoperative complications 
yet it is not considered in most preoperative risk models (Shahian et al., 2008). Since 
frailty is not accounted for in risk models, low BMI, which is a frailty parameter, may 
appear correlated with worse survival after cardiac surgery when it is in fact frailty that 
should be considered (Yamamoto et al., 2015). Correction for frailty in the present cohort 
via stratification by frailty status may explain mortality outcomes. 
 
Conclusion 
To the best of our knowledge, this is the first study directly comparing TAVR and 
SAVR in low BMI populations to propose the advantage of one treatment over the other. 
This study first demonstrated that low BMI patients fare worse than normal BMI SAVR 
patients in accordance with previous studies investigating the obesity paradox. Then 
within this low BMI population, SAVR and TAVR survival and postoperative outcomes 
were compared to determine which would be the preferred treatment in this challenging 
patient population. As expected, TAVR, which exhibited shorter hospital stays and 
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improved short-term outcomes, was proven to be a promising and reasonable alternative 
for low BMI patient populations requiring aortic valve replacement.   
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